Status:
COMPLETED
Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy
Lead Sponsor:
Sunnybrook Health Sciences Centre
Collaborating Sponsors:
Abbott
Conditions:
Lower Respiratory Tract Infection
Respiratory Syncytial Virus Infections
Eligibility:
All Genders
Brief Summary
The purpose of this study is to determine the utilization patterns and compliance rates of palivizumab, which is a monoclonal antibody therapy used to prevent respiratory syncytial virus infection.
Detailed Description
Respiratory syncytial virus (RSV) is the most important viral respiratory pathogen in children. Infection due to RSV represents a large public health burden; in Canada, it accounts for 5,800 hospitali...
Eligibility Criteria
Inclusion
- All children who receive at least one dose of palivizumab
Exclusion
- The child's parent or legal guardian could not communicate in either English or French
- The child had received palivizumab as part of a clinical trial during the study period
Key Trial Info
Start Date :
October 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 26 2017
Estimated Enrollment :
25003 Patients enrolled
Trial Details
Trial ID
NCT00420966
Start Date
October 1 2005
End Date
June 26 2017
Last Update
April 17 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Alberta Children's Hospital
Calgary, Alberta, Canada, T3B 6A8
2
McMaster Children's Hospital
Hamilton, Ontario, Canada, L8N 3Z5